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Background: Cytogenetic studies in Brazilian population about childhood acute lymphoblastic leukemia (ALL), the
most common childhood malignancy, are scarce. Moreover, Brazilian race is very heterogeneous and is made by
the confluence of people of several different origins, from the original Native Brazilians, with the influx of
Portuguese colonizers, Black African slaves, and recent European, Arab and Japanese immigration. The purpose of
this prospective, multicentric study was to assess the sociodemographic, clinic and cytogenetic characteristics of
the children treated for ALL in the Northeast region of Brazil.
Results: This study includes thirty patients between 4 months and 17 years old treated for ALL from January 1st,
2009 to November 30th, 2010. Cytogenetic analysis showed that in nineteen out of thirty patients (64%) presented
some chromosome abnormalities, in which 53% corresponds to numerical abnormalities, 21% structural and
numerical abnormalities, and 26% only structural changes. Moreover, seven patients presented complexes karyotype
not yet described in the literature. Taken together these results show the importance of the cytogenetic analysis in
ALL pediatric patients and illustrates that the studied population presented unexpected complexes karyotypes
which were correlated to poor outcome.
Conclusion: The results demonstrate the importance of banding cytogenetics for ALL diagnosis despite the use of
most modern techniques such as FISH and aCGH, and provide reliable insight into the ALL in Brazil.
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Acute lymphoblastic leukemia (ALL) comprises a group
of neoplasms characterized by clonal proliferation and
accumulation in the blast, hematopoietic immature cells
in the bone marrow. ALL is a disease characterized by
abnormal clonal proliferation of lymphoid precursors
which lose their ability to differentiate. It is the most
common malignancy in childhood, accounting for 80%
of all leukemia. Although it can occur at any age, its
incidence is highest among children from 2 to 5 years at
a rate of about 70%, decreasing among adolescents and* Correspondence: erica.gil@ig.com.br
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reproduction in any medium, provided the oryoung adults. The most useful prognostic indicators
in ALL are age, white blood cell count (WBC) and
immunologic markers. Cytogenetic analysis is of funda-
mental importance in the diagnosis, therapy, in monitoring
post-transplant bone marrow and to assess prognosis. It
is now possible to correlate the karyotype with other
recognized prognostic factors and to show that cytogenetic
studies can increase the precision of other clinical prognostic
features. Unfortunately, banding cytogenetic analysis of
leukemia is technically demanding, especially in the case of
ALL in infants. Clonal abnormalities are difficult to identify
because of frequent failure of standard chromosome-
preparing protocols. Moreover, clonal selection leads to a
high proportion of normal metaphases, masking abnormal
cells when a limited number of metaphases are analyzedThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 An unusual T-cell childhood acute lymphoblastic
leukemia harboring a yet unreported near-tetraploid
karyotype








1 F 4 White 7,3 20200 32000
2 F 7 White 12 11000 44000
3 M 5 Pardo 5,9 34700 33000
4 M 16 White 13 4600 63000
5 F 6 White 7,5 3100 32000
6 F 4 Black 8 4300 283000
7 M 3 Black 9 5800 336000
8 F 5 White 10,2 7800 165000
9 M 12 White 14 4400 249000
10 M 16 Black 8 1500 12000
11 M 17 Pardo 15 2800 19000
12 F 15 White 8 3000 52000
13 M 8 Pardo 11,3 3200 44900
14 F 0,4 Black 7,8 96600 65000
15 M 3 Pardo 9,2 21900 55000
16 F 3 Black 7,3 7900 26000
17 M 5 Pardo 6,8 35900 54000
18 M 2 White 5,7 6300 7000
19 M 3 White 8,4 50900 37000
20 F 1 Pardo 5,4 45700 26000
21 M 17 Pardo 7,1 60000 12000
22 F 7 Pardo 9,4 33200 83000
23 F 3 White 7,5 5600 45000
24 F 6 White 9,4 25000 38000
25 F 17 White 11,3 6500 18000
26 M 2 White 8,5 7400 45000
27 M 0,4 Pardo 10 13500 60000
28 M 6 White 7,8 2100 42000
29 M 5 White 6,9 5600 77000
30 M 16 Pardo 11,5 5300 160000
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is often incomplete, and it is not clear whether the abnor-
malities detected in a few analyzable metaphases are
representative of the whole leukemic clone [2,3].
Banding cytogenetic studies have identified numerical
and structural chromosomal abnormalities related to the
disease’s pathophysiologic characteristics. Frequency of
these abnormalities varies between pediatric and adult
patients. In children, pseudodiploidy is the most frequent
(40%), followed by hyperdiploidy with 51–65 chromosomes
(27%), hyperdiploidy with 47–50 chromosomes (15%),
hypodiploidy (6%), near-haploidy (1%), and the tetraploids
(1–2%) [4,5]. It has also been demonstrated that the
frequency with which chromosomal abnormalities are
observed varies among populations. In the Hindu popula-
tion, hyperdiploidy is infrequent (15%), in contrast with
the high frequency of hypodiploidy (38.4%). This behavior
has been attributed to unknown ethnic differences and
geographic factors [6,7].
We aimed to study the cytogenetic profile in pediatric
patients in several health institutions in the Brazilian
Northeast region, which is a very heterogeneous race
and no data on this feature is available in the literature.
Aim
To determine the cytogenetics profile of patients with ALL
during the period from January 1st, 2009 to November
30th, 2010 in the Northeast of Brazil.
Results
Patients characteristics
The sample comprised 30 patients diagnosed for ALL
between one and ten years old. The clinical characteristics
of the ALL patient populations are provided in Table 1.
Thirty seven percent (37%) were in the range between two
and five years old, with a mean age of 7,5 years old.
Regarding the sex, the male:female ratio was 1,3:1. The
complexity of racial classifications in Brazil reflects the
extent of miscegenation in Brazilian society, more people
would report themselves as white and pardo, which is a
mixed race of white and black people found only in Brazil
(47.7% and 42.4% of the population as of 2010, respect-
ively). For this reason we have separated the studied
population by skin color. Skin color was predominantly
white (50%) followed by pardo (33%) and black (17%).
According to medical records, the most common finding
of physical examination was hepatomegaly (73%), spleno-
megaly (70%) and lymphadenopathy (37%). The samples
(bone marrow and peripheral blood) were collected pre-
vious treatment in 83% of patients, whereas 17% were
submitted to collection after treatment has been initialized.
Seventy three percent (73%) of the patients’ hemoglobin
levels were less than 10 g/dL; 60% of patients showed
white blood cell (WBC) counts below 10.000/μL and 40%above this value. Considering the population who showed
WBC above 10.000/μL, 10% were above 50.000/μL.
Thrombocytopenia was observed in 83% of cases (Table 1).
Cytogenetics studies
Cytogenetic studies using G-banding techniques were
performed in 30 samples from ALL patients, where nine-
teen (64%) presented chromosomal alterations in the bone
marrow (BM) and peripheral blood (PB), seven patients
(23%) had normal karyotype and in four patients (13%)
it was not possible to analyze due to the absence of cell
growth (MI - mitotic index zero). Immunophenotype
analysis showed that 93% of patients had B-lineage
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the majority of cases (83%) were classified as pre-B
(Table 2). The small percentage of patients with T-ALL
may be associated with the proportion of adolescent
patients in this sample which were over 10 years.
Considering the nineteen patients who presented some
type of chromosomal abnormality, 53% were numerical
abnormalities, 21%, were structural and numericalTable 2 Results from G-banding technique related to imunop
N Karyotype
1 42 ~ 45,XX, -3[3], -13[3], -20[4][cp7] /46,XX [13]
3 45 ~ 56,XY, +4[3], +8[4], +11[3], +18[4], +20[3],
+21[4][cp20] / 46, XY [05]
4 46,XY [20]
5 46, XX [13]
6 46, XX [23]
7 46,XY, del(4)(p14?) [09] / 46,XY [11]
8 49 ~ 58,XX, +5[4], +9[3], +11[3], +15[4], +21[4],
+22[3] [cp9] / 46,XX [02]
9 46,XY [23]
11 48, XY, t (1;3) (q32;q27), +16, + mar[09] / 46, XY [14]
12 49 ~ 87, XX , +1[5], +3[4], +5[5], +7[5], +10[4], +12[6],
+13[04], add(14)(q32?), add(16)(p13.3), +18[6], +19[4],
+20[3], +21[6], +22[5][cp30]
13 49~54, XY, +3[3], +5[4], +8[4], +10[3], +17[4],
+21[4][cp11] / 46,XY [04]
14 46,XX,del(11)(q23) [17]
15 41~45,XY, -5[3], -7[3], -21[4][cp13] / 46,XY[07]
16 50~61,XX, +2[3], +4[4], +10[4], +12[3],+16[4], +19[5],
+21[4][cp7] / 46,XX[05]
17 48~60,XY, +3[4], +5[5], +7[4], +13[4], +17[3], +20[4],
+21[4][cp22] / 46,XY[05]
18 49~58,XY, +1[4], +6[4], +7[5], +22[3][cp9] / 46,XY[11]
19 46,XY, dup(1)(q31q44) [12] / 46,XY, dup(13)(q13q34)
[05] / 46,XY, der(21) t(7;21) (q21q36;q22.3) [04] / 46,XY [04]
20 46, XX, -7, + der 7 t(7;?)(q31;?) [30]
23 53~62,XX, +5[4], +8[4], +12[3], +16[4], +18[3],
+20[4], +21[4][cp7]/46,XX[15]
24 46,XX[19]
25 46,XX,t(9;22)(q34;q11), add(14)(q32) [20]
26 47,XY,i(7)(q10), +21c[22] /48,idem, +mar[4] / 48,
XY, i(7)(q10), +8, +21c [03]
27 46,XY [20]
28 38~45,XX, t(9;14), (q22?;q32?), del(20)(q?) [21]
29 46,XY [20]
30 36~45,XY, -4[3], -7[4], -9[3], -11[3], -22[4] [cp23] / 46,XY [03]
Legend: Samples 2, 10, 21 and 22 had null Mitotic Index (MI=0). Complex karyotype
leukemia type 1; L2: acute lymphoblastic leukemia type 2; L3: acute lymphoblastic l
i – isochromosome; add – additional chromosome; dup – duplication; der – derivat
of the chromosome; q – long arm of the chromosome, [ ] cells number analyzed.
Complex karyotype are highlighted in the table (N=7).abnormalities and 26% of the patients presented only
structural changes. In fourteen patients who presented
numeric chromosomal abnormalities and numeric alter-
ation with additional structural change, hyperdiploidy was
detected in eight patients (57%); hyperdiploidy with add-
itional change in three patients (22%); hypodiploidy in two
patients (14%), and finally, hypodiploidy with additional
changes in one patient (7%) (Table 2). Unusual or novelhenotype of each patient (1–30)
Cell type Classification of
cytogenetic alteration
Ploidy
ALL pre-B (L1) Numerical Hyperdiploidy
ALL pre-B (L1) Numerical Hyperdiploidy
ALL pre-B (L3) Normal -
ALL pre-B (L1) Normal -
ALL pre-B (L1) Normal -
ALL pre-B (L1) Structural Pseudodiploidy
ALL pre-B (L1) Numerical Hyperdiploidy
ALL pre-B (L1) Normal -
ALL pre-B (L2) Numerical + structural Hyperdiploidy+add
ALL Pre-B (L1) Numerical + structural Hyperdiploidy+add
ALL pre-B (L3) Numerical Hyperdiploidy
ALL pre-B (L1) Structural Pseudodiploidy
ALL pre-B (L1) Numerical Hypodiploidy
ALL pre-B (L1) Numerical Hyperdiploidy
ALL pre-B (L1) Numerical Hyperdiploidy
ALL pre-B (L1) Numerical Hyperdiploidy
ALL – B (L3) Structural Pseudodiploidy
ALL pre-B (L1) Numerical + structural Pseudodiploidy
ALL-B (L2) Numerical Hyperdiploidy
ALL pre-B (L3) Normal -
ALL pre-B (L1) Structural Pseudodiploidy
ALL pre-B (L1) Numerical + structural Hyperdiploidy+add
ALL – T (L2) Normal -
ALL pré-B (L2) Numerical + strutural Hypodiploidy+add
ALL pré-B Normal -
ALL pré-B Numerical Hypodiploidy
s are highlighted in bold character in the table (N=7). L1: acute lymphoblastic
eukemia type 3. inv - inversion; mar – marker chromosome; t – translocation;
ive chromosome; Ph+ - Philadelphia chromosome; del – deletion; p – short arm
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The karyotypes included in these cases presented hyper or
hypodiploidy with additional modifications, in addition to
the presence of cells with chromosomal markers (Table 2).
Patient 26 is a child with Down syndrome (DS) and acute
lymphoblastic leukemia (ALL) and is classified as complex
karyotype for presenting three different clones.
Discussion
Leukemia is the most common malignant neoplasms
in childhood, accounting for approximately 33% of all
malignancies in children under 14 years. Leukemia inci-
dence affects the 0–14 years old population with a fre-
quency of 1/25.000 individuals/ year, and the risk of
developing the disease within the first 10 years is 1/2.880.
After the discovery by Casperson [8] and Seabright [9] of
banding techniques, cytogenetic studies showed that about
50% of chromosomal abnormalities could be found in
acute leukemia. Several prospective studies using banding
techniques, have shown that the incidence of chromosomal
abnormalities varies between 55-94%, and found that some
changes are specific to particular cell subtype characterized
by immunophenotyping [10,11].
Considering our results, where fifteen patients presented
numerical chromosomal anomalies and numerical struc-
tural change, the hyperdiploidy was observed in ten pa-
tients (67%), which showed 54% only hyperdiploidy and
13% with hyperdiploidy with additional changes, whereas
hypodiploidy was found in 33% of patients. Of these, 13%
had some structural change. The additional structural
changes found were translocation, addition, duplication
and the presence of chromosome marker. Pérez-Vera
et al. [12] found that 22% patients presented normal
karyotype and 74% had some cytogenetic abnormalities.
Pui et al. [13] evaluated children diagnosed with ALL
and found hyperdiploidy in 26% of the patients. In 62% of
these cases were also detected chromosomal structural
changes.
According to the literature, it is considered complex
karyotypes more than one chromosomal abnormality and/
or an alteration which has not yet been described. We
observed seven novel complex karyotypes, among these,
a translocation between chromosomes 9 and 22 (Ph+)
with additional chromosome 14, duplication of chromo-
somes 1q and 13q, and a derivative of chromosome 21
translocated to chromosome 7, forming a derivative of
chromosome 7. It is important to highlight that these
complex karyotypes are considered unfavorable outcome.
One possible reason could be due to loss, gain or exchange
of genes that can promote often resistant to treatment.
The presence of the Philadelphia chromosome (Ph+)
or 9:22 translocation is usually found in about 3-5% of
the pediatric ALL, and is a modification of poor prognosis
[14]. It was observed the presence of a marker chromosomein three analyzed karyotype. The marker chromosomes
are complex rearrangements, usually consisting of centro-
meric heterochromatin, but may contain up to part of a
chromosome gene. It is practically impossible to establish
a precise relationship between the presence of this type of
chromosome and the phenotype of the patient. Thus, the
characterization of each chromosome marker becomes
imperative for this correlation [15].
Among the complex karyotypes it has been found a
Down syndrome (DS) presenting three clones cell. Accor-
ding to this finding, Silva et al. [16] found a karyotype of a
DS patient involving four clones. In the literature, the
relative risk of acute leukemia in the first 5 years has
been estimated to be 56 times that of non-DS individuals
with an equal frequency of acute myeloid leukemia (AML)
or acute lymphoblastic leukemia (ALL) [17].
This study could not be supplemented by molecular
approaches due to limitations in amount of patient ma-
terial and technical limitations as present in many re-
gions of the world. However, banding cytogenetics is the
basics for all further studies, especially in rare malignan-
cies like the here reported childhood leukemias.
Even though it is difficult to assume the outcome of
these patients, patients with complex cytogenetic changes
were classified as poor prognosis. The prognosis was
considered favorable in patients with hyperdiploidy or
with normal karyotype, and the age between one and six
years and/or leukocyte count close to normal. The inter-
mediate prognosis has been established for patients with
karyotypes who had only one structural chromosomal
alteration, aged between one and six years old, leukocyte
count above 20,000/μl and response to treatment assessed
by the presence of blasts in the PB. The poor prognosis
group presented complex karyotype, are age over 10 years
old and have the presence of blasts above 25% in PB.
Taken together these results show the importance of the
cytogenetic analysis in ALL pediatric patients and illustrates
that the studied population presented unexpected com-
plexes karyotypes which were correlated to poor outcome.
Material and methods
Study design
Patients included were issued from 5 different hospitals
of the state of Rio Grande do Norte: Hospital Infantil
Varela Santiago, Liga Norte-Riograndense Contra o Câncer,
Centro de Oncologia e Hematologia de Mossoró, Clínica
DNA Center during the period comprised between January
1st, 2009 and November 30, 2010. The inclusion criteria
were cytological and immunohistochemical diagnosis for
ALL; patients aged 0–18 years; availability of biological
material for cytogenetic analysis; laboratory data, such as
leukocyte counts, percentage of blast cells, count platelets
and hemoglobin; clinical data: presence or absence of
visceromegalies.
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Samples of bone marrow and peripheral blood of thirty
patients diagnosed with ALL of both sexes, aged from
4 months to 17 years old were collected. Cytogenetic
analysis on bone marrow cells and / or peripheral blood
was performed in the clinical laboratory of DNA Center.
The cytochemical diagnosis, morphological and immuno-
histochemical were provided by company Hemonorte
Hematology (Natal/RN). For cytogenetic analysis, 5 ml of
each bone marrow samples was collected in a syringe
containing sodium heparin. 2–5 ml of bone marrow
were collected in a tube containing 0,1 ml of Liquemine®
Roche®. For peripheral blood, 5 ml were collected in a
tube containing heparin. Samples were processed by
centrifugation (2.000 rpm).
Cell culture
The biological material was incubated overnight in
sterile conditions, in media containing 8% RPMI 1640
supplemented with 20% serum fetal bovine (FBS) and
glutamine (GIBCO Invitrogen®). The mitotic interruption
was proceed by adding 16ug/mL colchicine (GIBCO) and
incubated for 1 hour at 37°C. Cells were submitted to
hypotonic treatment with a solution of 0.075 M potassium
chloride for 20 minutes and the material were fixed with
3:1 (v/v) methanol: acetic acid. Cells were spread in the
slides and dried on a heating plate.
GTG-banding cytogenetics
Karyotyping was performed using standard techniques,
and the results were reported according to the International
System for Human Cytogenetic Nomenclature guidelines.
The slides were incubated in Sorensen’s buffer for 45 min
and then stained with Wright’s stain buffer for 2 minutes.
The slides were analyzed in an optical microscope
(Nikon-E200). A complex aberrant karyotype was defined
as three or more independent cytogenetic abnormalities in
at least two bone marrow cells.
Data collection
Data were collected and entered in Microsoft Excel®
spreadsheet, and later, there was a descriptive analysis
using SPSS Statistics 17.0, mean, median and standard
deviation of patient characteristics (age, sex, color) clinical
data (lymphadenopathy, hepatomegaly and splenomogaly),
chromosomal abnormalities present in the samples, prog-
nosis of abnormalities found and, finally, the parameters
hematology (hemoglobin, leukocytes and platelets).
Ethics consent
This study was approved in the Ethics Committee of
The Hospital Universitário Onofre Lopes (Universidade
Federal do Rio Grande do Norte) under the registration
number: 083/07. The written informed consent numberobtained from the patient’s parents for publication of this
case report is retained with the same Ethics Committee.
Abbreviations
ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; BM: Bone
marrow; DS: Down syndrome; PB: Peripheral blood; WBC: White blood cell.
Competing interests
Erica Gil holds a CNPq grant and TBPL holds a CAPES grant. The remaining
authors declare that they have no competing interests.
Authors’ contributions
EAG made all experiments and wrote the article, TBPL, TMOM, JMF, JMF,
ALACF, GDRL helped to write the manuscript and performed data collection
from medical records, EMRN helped to collect and process patient samples
and GBCJ helped to conduct the study as supervisor. All authors read and
approved the final manuscript.
Authors’ information
This study was conducted by Erica Gil, MPharm, in order to obtain Master
Degree at the Pharmaceutical Program at the Universidade Federal do Rio
Grande do Norte.
Acknowledgements
We are grateful to the physicians and to the patients of the four institutions
who had collaborated in this work.
Author details
1Departamento de Análises Clínicas e Toxicológicas/ Laboratório de
Imunologia, Universidade Federal do Rio Grande do Norte/, Rua Gen,
Gustavo Cordeiro De Farias S/N. Petrópolis, CEP 59010–180, Natal, RN, Brazil.
2Liga contra o Câncer. Departamento de Pesquisa Translacional, Av. Miguel
Castro 1355. Dix-Sept Rosado, CEP 59062–000, Natal, RN, Brazil.
Received: 17 April 2013 Accepted: 21 August 2013
Published: 11 September 2013
References
1. Garcia DR, Bhatt S, Manvelyan M, de Souza MT, Binato R, Aguiar TF,
Abdelhay E, Silva MLM: An unusual T-cell childhood acute lymphoblastic
leukemia harboring a yet unreported near-tetraploid karyotype.
Mol Cytogenet 2011, 4:20.
2. Morel F, Le Bris M-J, Douet-Guilbert N, Duchemin J, Herry A, Le Calvez G,
Marion V, Berthou C, De Braekeleer M: Loss of X chromosome in childhood
acute lymphoblastic leukemia. Cancer Genet Cytogenet 2003, 125:27–29.
3. Debatin KM, Stahnke K, Fulda S: Hematological disorders and apoptosis.
Nippon Naika Gakkai Zasshi 2003, 13:149–158.
4. Pui C-H, Relling MV, Downing JR: Acute lymphoblastic leukemia.
N Engl J Med 2004, 350:1535–1548.
5. Pui CH, Crist WM: Cytogenetic abnormalities in childhood acute
lymphoblastic leukemia correlates with clinical features and treatment
outcome. Leukemia lymphoma 1992, 7:259–274.
6. Perkins D, Brennan S, Carstairs K, Bailey D, Pantalony D, Poon A, Fernandes
B, Dubé I: Regional cancer cytogenetics: a report on 1,143 diagnostic
cases. Cancer Genet Cytogenet 1997, 96:64–80.
7. Amare P, Gladstone B, Varghese C, Pai S, Advani S: Clinical significance of
cytogenetic findings at diagnosis and in remission in childhood and
adult acute lymphoblastic leukemia: experience from India. Cancer Genet
Cytogenet 1999, 110:44–53.
8. Caspersson T, Zech L, Johansson C, Modest EJ: Identification of human
chromosomes by DNA-binding fluorescent agents. Chromosoma 1970,
30:215–227.
9. Seabright M: A rapid banding technique for human chromosomes.
Lance 1971, 2:971–972.
10. Al-Achkar W, Aljapawe A, Othman MAK, Wafa A: A de novo acute myeloid
leukemia (AML-M4) case with a complex karyotype and yet unreported
breakpoints. Mol Cytogenet 2013, 6:18.
11. Zakaria Z, Md Ahid MF, Ismail A, Ten SK, Mohamad Nor N, Kamaluddin NR,
Esa E, Kah Yuen L, Abdul Rahman EJ, Osman R: Chromosomal Aberrations
in ETV6/RUNX1-positive Childhood Acute Lymphoblastic Leukemia using
Gil et al. Molecular Cytogenetics 2013, 6:37 Page 6 of 6
http://www.molecularcytogenetics.org/content/6/1/37244 K Oligonucleotide Array Comparative Genomic Hybridization.
Mol Cytogenet 2012, 5:41.
12. Perez-Vera P, Mujica-Sanchez M, Carnevale A, Rivera-Luna R, Paredes R, Martinez
A, Frias S: Cytogenetics in acute lymphoblastic leukemia in Mexican children:
an institutional experience. Arch Med Res 2001, 32:202–207.
13. Pui CH, Raimondi SC, Dodge RK, Rivera GK, Fuchs LA, Abromowitch M, Look
AT, Furman WL, Crist WM, Williams DL: Prognostic importance of structural
chromosomal abnormalities in children with hyperdiploid (greater than
50 chromosomes) acute lymphoblastic leukemia. Blood 1989,
73:1963–1967.
14. Hasle H: Pattern of malignant disorders in individuals with Down’s
syndrome. Lancet Oncol 2001, 2:429–436.
15. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A,
Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR:
Karyotypic analysis predicts outcome of preremission and postremission
therapy in adult acute myeloid leukemia: a Southwest Oncology Group/
Eastern Cooperative Oncology Group Study. Blood 2000, 96:4075–4083.
16. Silva MLM, Ornellas De Souza MH, Ribeiro RC, Land MGP, Boulhosa De
Azevedo AM, Vasconcelos F, Otero L, Vasconcelos Z, Bouzas LF, Abdelhay E:
Cytogenetic analysis of 100 consecutive newly diagnosed cases of acute
lymphoblastic leukemia in Rio de Janeiro. Cancer Genet Cytogenet 2002,
137:85–90.
17. Hasle H, Clemmensen IH, Mikkelsen M: Risks of leukaemia and solid
tumours in individuals with Down’s syndrome. Lance 2000, 355:165–169.
doi:10.1186/1755-8166-6-37
Cite this article as: Gil et al.: Banding cytogenetic analysis in pediatric
patients with acute lymphoblastic leukemia (ALL) in a Brazilian
population. Molecular Cytogenetics 2013 6:37.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
